Skip to Content
Opening Bell
News
YahooOctober 1, 2026 at 12:38 PM NY26 Days Ago

Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says

Merck's (MRK) data from a phase 2b study evaluating tulisokibart in hidradenitis suppurativa looks s

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo

Read at Source